Search

UCB SA

Cerrado

SectorSanidad

172.5 1.02

Resumen

Variación precio

24h

Actual

Mínimo

168.55

Máximo

173.55

Métricas clave

By Trading Economics

Ingresos

857M

Ventas

3.4B

P/B

Media del Sector

31.06

39.564

Rentabilidad por dividendo

0.83

Margen de beneficios

25.498

Empleados

9,052

EBITDA

1.3B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+19.23% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.83%

2.40%

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-3.4B

32B

Apertura anterior

171.48

Cierre anterior

172.5

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

133 / 376 Clasificación en Healthcare

UCB SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

13 jul 2025, 23:54 UTC

Charlas de Mercado

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

13 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 jul 2025, 23:39 UTC

Charlas de Mercado

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 jul 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:13 UTC

Charlas de Mercado

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 jul 2025, 11:00 UTC

Adquisiciones, fusiones, absorciones

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 jul 2025, 02:24 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

UCB SA previsión

Precio Objetivo

By TipRanks

19.23% repunte

Estimación a 12 Meses

Media 94.86 EUR  19.23%

Máximo 125 EUR

Mínimo 74 EUR

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para UCB SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

4

Comprar

1

Mantener

2

Vender

Sentimiento

By Acuity

133 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.